A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer (Q74599522)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

review article

1 reference

title

A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

A A Adjei

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 February 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

published in

Cancer Treatment Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

35-53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

cites work

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Chemotherapy of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

The role of external radiation and brachytherapy in unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Report by the radiation therapy oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small-cell lung cancer treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Impact of tumor control on survival in carcinoma of the lung treated with irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Treatment of metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

New drugs for treating small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Small cell lung cancer: etiology, biology, clinical features, staging, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

New drugs in non-small cell lung cancer. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Mechanism of action of taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

1 reference

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Effects of Taxotere on murine and human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Motility and invasive potency of murine T-lymphoma cells: effect of microtubule inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

In vitro studies of Taxol as a radiation sensitizer in human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

The taxoids: paclitaxel and docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Paclitaxel premedication regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Safety profile of single-dose dexamethasone premedication for paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistance studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

CPT-11 Converting Enzyme from Rat Serum: Purification and Some Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase I and pharmacologic study of topotecan in patients with impaired renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of topotecan in metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Clinical, toxicological and pharmacological aspects of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Preclinical characteristics of gemcitabine.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Radiosensitizing nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Gemcitabine in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Kinetic Analysis of Combination Effect of Navelbine (KW-2307) with Cisplatin against Human Lung Adenocarcinoma PC-12 Cells in Culture

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Cisplatin-vinorelbine combination chemotherapy in locally advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Carboplatin and vinorelbine in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990070-6

7 January 2021

10.1016/S0305-7372(98)90070-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9606367%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference